{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:55:27Z","timestamp":1786985727353,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.carrev.2016.09.011","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T01:20:42Z","timestamp":1475630442000},"page":"535-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of heparin, bivalirudin, and different glycoprotein IIb\/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis"],"prefix":"10.1016","volume":"17","author":[{"given":"Michael J.","family":"Lipinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Michael A.","family":"Gaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Torguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector M.","family":"Garcia-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto D.","family":"Pichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell F.","family":"Satler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2016.09.011_bb0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/01.CIR.93.2.215","article-title":"A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation","volume":"93","author":"Hall","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2016.09.011_bb0010","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2016.09.011_bb0020","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0735-1097(01)01165-2","article-title":"Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting","volume":"37","author":"Neumann","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jcin.2014.10.003","article-title":"Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb\/IIIa inhibitors in patients with acute coronary syndrome","volume":"8","author":"Navarese","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2016.09.011_bb0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.carrev.2014.08.010","article-title":"Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials","volume":"15","author":"Lipinski","year":"2014","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.carrev.2016.09.011_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2015.04.012","article-title":"Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap","volume":"170","author":"Alexopoulos","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2016.09.011_bb0040","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCOUTCOMES.110.960294","article-title":"Upstream use of small-molecule glycoprotein IIb\/IIIa inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials","volume":"4","author":"Tricoci","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.carrev.2016.09.011_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/eurheartj\/ehp376","article-title":"Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials","volume":"31","author":"Valgimigli","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2016.09.011_bb0050","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1517\/14740338.2010.507189","article-title":"Safety evaluation of tirofiban","volume":"9","author":"Valgimigli","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.carrev.2016.09.011_bb0055","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.carrev.2016.09.011_bb0060","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/096228029600500402","article-title":"Markov chain Monte Carlo methods in biostatistics","volume":"5","author":"Gelman","year":"1996","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.carrev.2016.09.011_bb0065","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jama.2013.277165","article-title":"Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial","volume":"310","author":"Steg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2016.09.011_bb0070","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2016.09.011_bb0075","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","article-title":"Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the acute catheterization and urgent intervention triage strategy (ACUITY) trial","volume":"369","author":"Stone","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2016.09.011_bb0080","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/CIRCULATIONAHA.108.833236","volume":"119","author":"Valgimigli","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2016.09.011_bb0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jacc.2004.03.042","article-title":"The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE trial","volume":"44","author":"Valgimigli","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjcard.2004.03.026","article-title":"Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function","volume":"94","author":"Danzi","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0095","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jacc.2004.06.050","article-title":"Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction","volume":"44","author":"Ernst","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0100","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jacc.2005.11.012","article-title":"Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial","volume":"47","author":"Bolognese","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2012.01.006","volume":"5","author":"Valgimigli","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2016.09.011_bb0110","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1093\/eurheartj\/ehn467","article-title":"Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial","volume":"29","author":"Marzocchi","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2016.09.011_bb0115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/joic.12044","article-title":"Short-term effect of upstream administration in comparison to deferred injection of tirofiban on patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"26","author":"Jia","year":"2013","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0120","doi-asserted-by":"crossref","first-page":"344.e1","DOI":"10.1016\/j.ahj.2007.05.007","article-title":"Optimal platelet inhibition in patients undergoing PCI: data from the multicenter registry of high-risk percutaneous coronary intervention and adequate platelet inhibition (MR PCI) study","volume":"154","author":"Mardikar","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2016.09.011_bb0125","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1001\/jama.299.15.joc80026","article-title":"Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial","volume":"299","author":"Valgimigli","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2016.09.011_bb0130","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.jacc.2009.11.091","article-title":"Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome","volume":"55","author":"ten Berg","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2459\/JCM.0b013e32832180d9","article-title":"Glycoprotein IIB\/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study","volume":"10","author":"Talarico","year":"2009","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.carrev.2016.09.011_bb0140","doi-asserted-by":"crossref","first-page":"e9641","DOI":"10.5812\/ircmj.9641","article-title":"Effect of early treatment with tirofiban on initial TIMI grade 3 flow of patients with ST elevation myocardial infarction","volume":"16","author":"Salarifar","year":"2014","journal-title":"Iran Red Crescent Med J"},{"key":"10.1016\/j.carrev.2016.09.011_bb0145","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1001\/jama.293.17.2109","article-title":"Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial","volume":"293","author":"Valgimigli","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2016.09.011_bb0150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/1995-705X.102145","article-title":"High bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI - the Tamip study","volume":"13","author":"Balghith","year":"2012","journal-title":"Heart Views"},{"key":"10.1016\/j.carrev.2016.09.011_bb0155","first-page":"1001","volume":"77","author":"Moliterno","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2016.09.011_bb0160","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1161\/01.CIR.0000126284.40075.98","article-title":"Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone","volume":"109","author":"Antoniucci","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2016.09.011_bb0165","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2016.09.011_bb0170","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.108.818617","article-title":"Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial","volume":"119","author":"Mehilli","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2016.09.011_bb0175","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/01.CIR.0000087601.45803.86","article-title":"Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial","volume":"108","author":"Tcheng","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2016.09.011_bb0180","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mhj.2002.122173","article-title":"Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the comparison of abciximab complications with Hirulog for ischemic events trial (CACHET)","volume":"143","author":"Lincoff","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2016.09.011_bb0185","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2009.08.093","article-title":"Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI trial","volume":"56","author":"Zeymer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0190","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0735-1097(99)00635-X","article-title":"Effect of glycoprotein IIb\/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction","volume":"35","author":"Neumann","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0195","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa031859","article-title":"A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel","volume":"350","author":"Kastrati","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2016.09.011_bb0200","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2016.09.011_bb0205","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2016.09.011_bb0210","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1161\/01.CIR.0000148956.93631.4D","article-title":"Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel","volume":"110","author":"Mehilli","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2016.09.011_bb0215","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/CIRCINTERVENTIONS.108.847582.108.847582","volume":"2","author":"Le May","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2016.09.011_bb0220","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jacc.2008.10.045","volume":"53","author":"Gurbel","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0225","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","volume":"356","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2016.09.011_bb0230","doi-asserted-by":"crossref","first-page":"835.e1","DOI":"10.1016\/j.ahj.2012.02.009","article-title":"Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to avoid myocardial necrosis trial","volume":"163","author":"Biondi-Zoccai","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2016.09.011_bb0235","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.amjcard.2012.04.017","volume":"110","author":"Patti","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0240","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.amjcard.2009.12.001","article-title":"Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the antithrombotic regimens aNd outcome [ARNO] trial)","volume":"105","author":"Parodi","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2016.09.011_bb0245","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/eurheartj\/ehu182","article-title":"Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction","volume":"35","author":"Schulz","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2016.09.011_bb0250","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2016.09.011_bb0255","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehu214","article-title":"Bivalirudin is superior to heparins alone with bailout GP IIb\/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial","author":"Zeymer","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2016.09.011_bb0260","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2016.09.011_bb0265","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2016.09.011_bb0270","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2016.09.011_bb0275","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jcin.2014.10.015","article-title":"Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting","volume":"8","author":"Briguori","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2016.09.011_bb0280","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.3760\/cma.j.issn.0366-6999.20122569","article-title":"Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention","volume":"126","author":"Xiang","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.carrev.2016.09.011_bb0285","article-title":"Bivalirudin, glycoprotein inhibitor, and heparin use and association with outcomes of primary percutaneous coronary intervention in the United Kingdom","author":"Sirker","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2016.09.011_bb0290","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","article-title":"Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials","volume":"384","author":"Cavender","year":"2014","journal-title":"Lancet"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838916302779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838916302779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:12:12Z","timestamp":1761559932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838916302779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1553838916302779"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2016.09.011","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of heparin, bivalirudin, and different glycoprotein IIb\/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2016.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}